ENZN
Price
$0.11
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
8.53M
EXEL
Price
$46.15
Change
+$1.85 (+4.18%)
Updated
Jul 3 closing price
Capitalization
12.59B
37 days until earnings call
Interact to see
Advertisement

ENZN vs EXEL

Header iconENZN vs EXEL Comparison
Open Charts ENZN vs EXELBanner chart's image
Enzon Pharmaceuticals
Price$0.11
Change-$0.00 (-0.00%)
Volume$18.23K
Capitalization8.53M
Exelixis
Price$46.15
Change+$1.85 (+4.18%)
Volume$6.04M
Capitalization12.59B
ENZN vs EXEL Comparison Chart in %
Loading...
ENZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENZN vs. EXEL commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENZN is a Hold and EXEL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (ENZN: $0.11 vs. EXEL: $46.15)
Brand notoriety: ENZN: Not notable vs. EXEL: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENZN: 34% vs. EXEL: 167%
Market capitalization -- ENZN: $8.53M vs. EXEL: $12.59B
ENZN [@Biotechnology] is valued at $8.53M. EXEL’s [@Biotechnology] market capitalization is $12.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENZN’s FA Score shows that 1 FA rating(s) are green whileEXEL’s FA Score has 2 green FA rating(s).

  • ENZN’s FA Score: 1 green, 4 red.
  • EXEL’s FA Score: 2 green, 3 red.
According to our system of comparison, EXEL is a better buy in the long-term than ENZN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENZN’s TA Score shows that 6 TA indicator(s) are bullish while EXEL’s TA Score has 4 bullish TA indicator(s).

  • ENZN’s TA Score: 6 bullish, 4 bearish.
  • EXEL’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ENZN is a better buy in the short-term than EXEL.

Price Growth

ENZN (@Biotechnology) experienced а +14.90% price change this week, while EXEL (@Biotechnology) price change was +7.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

EXEL is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($12.6B) has a higher market cap than ENZN($8.53M). ENZN has higher P/E ratio than EXEL: ENZN (96.10) vs EXEL (21.07). EXEL YTD gains are higher at: 38.589 vs. ENZN (-26.393). EXEL has higher annual earnings (EBITDA): 844M vs. ENZN (-2M). EXEL has more cash in the bank: 1.03B vs. ENZN (45M). ENZN has less debt than EXEL: ENZN (116M) vs EXEL (187M). EXEL has higher revenues than ENZN: EXEL (2.3B) vs ENZN (26K).
ENZNEXELENZN / EXEL
Capitalization8.53M12.6B0%
EBITDA-2M844M-0%
Gain YTD-26.39338.589-68%
P/E Ratio96.1021.07456%
Revenue26K2.3B0%
Total Cash45M1.03B4%
Total Debt116M187M62%
FUNDAMENTALS RATINGS
ENZN vs EXEL: Fundamental Ratings
ENZN
EXEL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
10019
SMR RATING
1..100
9732
PRICE GROWTH RATING
1..100
5138
P/E GROWTH RATING
1..100
1192
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (73) in the Biotechnology industry is in the same range as ENZN (85). This means that EXEL’s stock grew similarly to ENZN’s over the last 12 months.

EXEL's Profit vs Risk Rating (19) in the Biotechnology industry is significantly better than the same rating for ENZN (100). This means that EXEL’s stock grew significantly faster than ENZN’s over the last 12 months.

EXEL's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for ENZN (97). This means that EXEL’s stock grew somewhat faster than ENZN’s over the last 12 months.

EXEL's Price Growth Rating (38) in the Biotechnology industry is in the same range as ENZN (51). This means that EXEL’s stock grew similarly to ENZN’s over the last 12 months.

ENZN's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for EXEL (92). This means that ENZN’s stock grew significantly faster than EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENZNEXEL
RSI
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
72%
Momentum
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
71%
MACD
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
66%
Advances
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 4 days ago
65%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 11 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
61%
Aroon
ODDS (%)
Bullish Trend 4 days ago
80%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ENZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PILBF1.010.09
+9.60%
PILBARA MINERALS LTD
SGPTF0.220.01
+3.63%
SAGE POTASH CORP
JGCCF8.50N/A
N/A
JGC Holdings Corporation
NWPHF9.36N/A
N/A
Newron Pharmaceuticals SPA
FIDS21.00N/A
N/A
FNB, Inc.

ENZN and

Correlation & Price change

A.I.dvisor tells us that ENZN and CLDX have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENZN and CLDX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENZN
1D Price
Change %
ENZN100%
+1.95%
CLDX - ENZN
8%
Poorly correlated
-0.50%
HALO - ENZN
2%
Poorly correlated
+0.30%
INCY - ENZN
2%
Poorly correlated
+0.41%
EXEL - ENZN
2%
Poorly correlated
+4.18%
ERNA - ENZN
-4%
Poorly correlated
+1.01%
More

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with JAZZ. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then JAZZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+4.18%
JAZZ - EXEL
35%
Loosely correlated
-0.43%
RIGL - EXEL
29%
Poorly correlated
+1.50%
RVMD - EXEL
28%
Poorly correlated
+1.83%
CGON - EXEL
28%
Poorly correlated
+0.82%
UTHR - EXEL
28%
Poorly correlated
-0.25%
More